The use of CD19 CAR T cells has been successful for treating R/R B cell malignancies such as ALL [18] or DLBCL, leading to several drug approvals by regulatory agencies, and this approach will be approved for other B-malignancies such as MM or CLL, and in the near future for AML and solid tumors in the long term. The gene discussed is CD19; the disease is Miyoshi myopathy.